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and complications, and patient co-morbidities. To assist in medical decision 
making from clinical and cost perspectives, we have developed a simulation 
model that synthesizes the evidence on NMIBC using the Archimedes Model 
platform. Methods: The NMIBC model consists of a patient generation compo-
nent in which virtual patients are constructed from SEER case listings; a natural 
history component that captures recurrence, progression, and bladder cancer 
mortality; a health care component that captures the effects of treatments, tests, 
and surveillance; and a cost component that tracks the costs relevant to bladder 
cancer care. Using this model, we performed a 5-year virtual clinical trial of 350 
NMIBC patients with demonstrated Bacillus Calmette-Guerin failure, randomized 
to either immediate cystectomy or conservative treatment with Mitomycin C 
(MMC) intravesical therapy. The model is integrated within the Archimedes Model 
platform, which captures the effects of both NMIBC and patient co-morbidities. 
This model, validated against 5 published studies, gives recurrence and progres-
sion rates within ±20% of published results. Results: The virtual clinical trial 
shows a 5-yr cystectomy rate of 51% in the MMC arm, with an average delay to 
cystectomy of 0.84 yr (median 0.44 yr). The immediate cystectomy arm saves 0.26 
life years (LY) and $5598 in total bladder cancer cost per patient compared to the 
MMC arm. ConClusions: We have constructed a dynamic, quantitative model of 
NMIBC that can predict clinical and economic outcomes and help optimize treat-
ment and surveillance guidelines. The virtual clinical trial quantifies LY and cost 
outcomes for immediate cystectomy versus conservative therapy, and provides a 
valuable tool for trial design and health economic analyses.
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objeCtives: To determine the cost-effectiveness of bendamustine-rituximab 
(Ben-R) versus fludarabine-rituximab (Fdb-R) in patients with iNHL who have pro-
gressed following treatment with rituximab or a rituximab-containing regimen in 
Colombia. Methods: An economic model was constructed from the Colombian 
health system perspective, with a 35-year (lifetime) horizon and a discount rate 
of 3%. The model included three health states, progression-free (PF), progressive 
disease (PD), and death, which were associated with utility weights of 0.81, 0.62 
and 0, respectively. Clinical inputs (response rates, Kaplan-Meier curves, haz-
ard ratios (HRs) and adverse event rates) were from the Stil NHL 2-2003 study. 
Resource use data were from interviews with three Colombian hematologists 
treating iNHL patients. Unit costs were from ISS and SISPRO report and were 
expressed as 2013 Colombian Pesos. Univariate and probabilistic sensitivity 
analyses were conducted to determine the key drivers of cost-effectiveness, and 
uncertainty around the results, respectively. Results: Total lifetime cost of Ben-R 
was $291,192,912 and total cost of Fdb-R was $260,463,392. Ben-R patients accrued 
more LYs (6.47 vs. 5.15), QALYs (4.66 vs. 3.56), and PFLYs (3.57 vs. 2.05) compared 
to Fdb-R patients. The ICERs were $23,286,360 (cost per LY), $27,956,124 (cost per 
QALY) and $20,259,063 (cost per PF LY). Univariate sensitivity analysis revealed that 
the ICER per LY was most sensitive to the PFS and OS HRs for Ben-R vs Fdb-R, the 
number of treatment cycles, and the cost of bendamustine. Probabilistic sensitiv-
ity analysis with 1,000 iterations estimated that Ben-R had a 52% chance of being 
cost-effective, compared to Fdb-R, at a willingness to pay (WTP) of $59M per LY, 
rising to a plateau of about 93% at a WTP of $175M and above. ConClusions: At 
a willingness-to-pay of $59M (three times the GDP per capita of Colombia) Ben-R 
is a cost-effective alternative to Fdb-R.
PCN95
CosT-effeCTiveNess of The oPTiCal imagiNg ageNT 
hexamiNolevuliNaTe foR PaTieNTs wiTh NoN-musCle iNvasive 
BladdeR CaNCeR
Marteau F.1, Kornowski A.1, Bennison C.2, Tempest M.J.2, Mariappan P.3, Witjes J.A.4
1Ipsen Pharma SAS, Boulogne-Billancourt, France, 2Pharmerit Ltd., York, UK, 3Western General 
Hospital, Edinburgh, UK, 4Radboud University Medical Centre, Nijmegen, The Netherlands
objeCtives: Hexaminolevulinate (HAL) is an optical imaging agent used as an 
adjunct to white light cystoscopy (WLC) in the diagnosis and management of non-
muscle invasive bladder cancer (NMIBC). The objective of this study was to model 
the cost-effectiveness of HAL-assisted blue light cystoscopy (HAL-BLC) compared to 
WLC alone when used at initial transurethral resection of bladder tumours (TURB) 
from the perspective of the National Health Service (NHS) in England and Wales 
using available clinical data. Methods: A two-part model was developed to esti-
mate the incremental cost-effectiveness of HAL-BLC at initial TURB for patients 
positively diagnosed in the outpatient setting with NMIBC over a lifetime hori-
zon. This consisted of a short-term decision tree, which estimated the outcome 
of the outpatient diagnostic procedure and inpatient TURB, and a Markov cohort 
model, used to extrapolate long term outcomes. Clinical effectiveness evidence on 
recurrence was taken from a recent meta-analysis of NMIBC with HAL-BLC, costs 
were derived from NHS reference costs, and utilities and disease evolution were 
from the literature. Results: Despite additional treatment and equipment costs, 
base case results suggest that HAL-BLC is a dominant strategy as an adjunct to 
WLC compared to WLC only, when used at initial TURB for patients diagnosed with 
NMIBC. HAL-BLC is expected to be associated with 0.060 incremental QALYs and 
cost-savings of £391 per patient resulting from fewer recurrences and fewer associ-
ated surgical procedures (33 avoided TURBs/149 positively-diagnosed patients), in 
turn due to improved completeness of lesion resection and better tumour staging. 
Probabilistic sensitivity analyses indicated that HAL-BLC was dominant in 91.9% of 
iterations. ConClusions: HAL-BLC as an adjunct to WLC was shown to be a domi-
to assess the uncertainty on the parameters, univariate sensitivity analyses were 
performed. Results: At 100 years, compared to only screening for cervix cancer, 
S2 scenario reduced 73% of the genital warts cases, 92% of the cancer cases in 
women and 87% of the cancer cases in men; while S1 strategy only reduced 56%, 
87% and 63% the cases of the different diseases, respectively. S2 strategy was less 
costly compared with S1: during the first 10 years reduced more than € 25 million 
for the NHS and more than € 282 million over 100 years. The savings over 100 years 
varied between € 141 million and € 1,268 million when considering a 5% or 0% dis-
count, respectively. ConClusions: Vaccinating boys and girls between 11 and 26 
years would significantly reduce the epidemiological and economic burden of HPV 
related diseases in Spain.
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objeCtives: To compare the impact of the quadrivalent (QV) (HPV 6/11/16/18) and 
bivalent (BV) (HPV 16/18) vaccines against HPV in Spain. Methods: A population-
based compartmental dynamic transmission model of HPV developed in the US was 
partially adapted to Spain updating epidemiological data of HPV related diseases, 
the vaccination coverage and direct costs of the diseases. The reduction of the 
number of cases related to HPV and savings associated with the following strategies 
were compared: A) cervix cancer screening (CCS) of women between 25-65 years, 
every 3-5 years and a vaccination program of girls between 11-26 years with the QV 
vaccine; B) CCS+BV vaccine. The analysis was performed from the National Health 
System (NHS) perspective, costs were discounted by 3% and the time horizon was 
100 years. Univariate sensitivity analyses were performed to assess the uncertainty 
on the parameters. Results: At 100 years, considering the current indications of 
the vaccines, lifetime protection against HPV vaccine types and 20 years of cross-
protection, both strategies reduced 208 cases of vulvar and vaginal cancers and 
22,796 cases of CIN2+. The strategy CCS+QV vaccine reduced 18,689 additional cases 
of genital warts due to the protection against 6/11 HPV types, but 4 less cases of 
cervix cancer and 359 less cases of CIN2+ due to better cross-protection of the BV 
vaccine. Nevertheless, savings accumulated during 100 years due to the reduction 
of genital warts cases (€ 215.7 million) compensated the cost associated to cervix 
cancers and CIN2+ that the BV vaccine additionally reduced (€ 3 and € 27.1 mil-
lion, respectively). Therefore, during 100 years the QV vaccine saves € 185.4 million 
more than the BV vaccine. The sensitivity analyses confirmed the stability of the 
results. ConClusions: The QV vaccine provides higher cost savings to the NHS 
compared to the BV vaccine due to the additional efficacy against HPV 6/11 types.
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objeCtives: As with many types of cancer, treatment of multiple myeloma (MM) 
is characterised by sequential treatment lines consisting of innovative expensive 
drugs such as thalidomide, bortezomib and lenalidomide. While cost-effectiveness 
of single treatments has been studied, a full disease model evaluating treatments 
sequentially is currently lacking, consequently, high uncertainty exists on incremen-
tal cost-effectiveness ratios. Therefore, we aimed to take a look at the big picture 
and calculate real-world costs and effects for commonly used treatment pathways 
for MM. Methods: We developed a patient-level simulation (PLS) for elderly (> 65) 
MM patients diagnosed since 2004. Real-world data (N= 621) including patient and 
disease characteristics, treatment information as well as resource use was collected 
from hospital registrations and medical files. Five treatment categories per line 
were observed resulting in 19 commonly used treatment pathways. Parametric 
survival models including patient characteristics such as age, performance sta-
tus, comorbidities and laboratory values were used to predict time to an event, 
i.e. the start of a new treatment or death. Logistic regression determined which of 
the two competing events occurred. The sensitivity of parameters was explored 
through sensitivity analyses. Results: In total, the costs and effects of 19 treat-
ment pathways were calculated. Depending on the treatment sequencing, total 
costs ranged from € 40,810 (Melphalan/Prednison-Thalidomide-Other) to € 132,613 
(Bortezomib-Lenalidomde-Other) while overall survival ranged from 28 to 50 months 
for Bortezomib-Lenalidomide-Thalidomide and Lenalidomide-Bortezomib-Other, 
respectively. Costs per quality-adjusted-life-year (QALY) were between € 21,881 
(Melphalan/Prednison-Thalidomide-Other) and € 57,743 (Bortezomib-Lenalidomide-
Other). Compared to real-world prescription, QALYs could be increased at a cost 
of € 33,785 per QALY (Lenalidomide-Thalidomide-Other). ConClusions: The 
cost-effectiveness of 19 treatment pathways for MM patients was calculated and 
revealed that real-world treatment could be improved at a cost of € 33,785 per QALY. 
Our PLS model proved to be a reliable and robust approach to study entire treat-
ment pathways for MM.
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objeCtives: Non-muscle invasive bladder cancer (NMIBC) is a complex disease 
with wide variation in risks of recurrence and progression, treatment efficacy 
